Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells 3,080 Shares of Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the transaction, the director now owns 107,976 shares of the company’s stock, valued at approximately $2,257,778.16. The trade was a 2.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Denali Therapeutics Stock Up 2.0 %

Shares of NASDAQ DNLI traded up $0.42 during trading on Friday, hitting $21.26. 629,332 shares of the company traded hands, compared to its average volume of 663,916. The company has a 50-day moving average price of $24.72 and a 200-day moving average price of $24.84. The firm has a market capitalization of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.35. Denali Therapeutics Inc. has a 1 year low of $14.56 and a 1 year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the previous year, the firm posted ($0.72) EPS. Research analysts predict that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Raymond James reiterated a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. HC Wainwright reiterated a “buy” rating and set a $90.00 target price on shares of Denali Therapeutics in a research report on Thursday, November 7th. William Blair started coverage on shares of Denali Therapeutics in a report on Friday. They issued an “outperform” rating for the company. Stifel Nicolaus raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a report on Monday, December 16th. Finally, Jefferies Financial Group boosted their target price on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, Denali Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $40.40.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in DNLI. FMR LLC raised its holdings in shares of Denali Therapeutics by 3,234.3% during the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after buying an additional 7,596,508 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Denali Therapeutics by 63.2% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock valued at $109,223,000 after purchasing an additional 1,451,770 shares during the period. Point72 Asset Management L.P. acquired a new stake in Denali Therapeutics during the 2nd quarter valued at $24,454,000. Wellington Management Group LLP grew its holdings in Denali Therapeutics by 9.2% during the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after purchasing an additional 903,683 shares in the last quarter. Finally, Integral Health Asset Management LLC acquired a new position in Denali Therapeutics in the 2nd quarter worth $7,546,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.